Publication

Article

Pharmaceutical Executive

Pharmaceutical Executive: April 2025
Volume45
Issue 3

Pharmaceutical Executive: April 2025 Interactive Digital Edition

View the Pharmaceutical Executive April 2025 issue in an interactive format.

Click here to view our interactive April 2025 issue!

Download Issue PDF
Articles in this issue
Pharmaceutical Executive: April 2025 Interactive Digital Edition
Pharmaceutical Executive: April 2025 Interactive Digital Edition
‘Earning’ Power
‘Earning’ Power
Milan Kalawadia: Carving Out New Pathways
Milan Kalawadia: Carving Out New Pathways
Bringing Biotech Innovation Across Borders
Bringing Biotech Innovation Across Borders
Using AI to Predict Launch Success
Using AI to Predict Launch Success
Improving Your Earned Media Strategy: Tips and Insights
Improving Your Earned Media Strategy: Tips and Insights

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Pharmaceutical Executive
Peter Rubin
Related Content
Stock.adobe.com
September 30th 2025

AstraZeneca Announces Plans to Harmonize Global Listing Structure for Stock Exchanges Alongside Positive Enhertu Updates

Mike Hollan
Pharmaceutical Executive
September 30th 2025

Pharmaceutical Executive Daily: September 29, 2025

Nicholas Jacobus
Stock.adobe.com
September 30th 2025

Genmab Acquires Merus in $8 Billion Transaction Agreement Including Late-Stage Breakthrough Therapy Asset Petosemtamab

Nicholas Jacobus
Pharmaceutical Executive
September 30th 2025

Pharmaceutical Executive Daily: September 26, 2025

Nicholas Jacobus
Image Credit: Adobe Stock Images/Марина Терехова. Tremfya was initially approved for adults with psoriasis in 2017 and for adults with active psoriatic arthritis in 2020.
September 30th 2025

FDA Approves Tremfya for Children With Plaque Psoriasis, Psoriatic Arthritis

Davy James
Professor Niels Riedemann, MD
September 30th 2025

Building a Business During a Pandemic: Q&A with Professor Niels Riedemann, MD

Mike Hollan
© 2025 MJH Life Sciences

All rights reserved.